Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
681-700 of 2,120 trials

Urothelial Cancer: Nivolumab with Relatlimab

We are studying a combination of nivolumab and relatlimab as a pre-surgery treatment for muscle-invasive bladder cancer. The goal is to see if this approach is effective and safe compared to nivolumab alone.

Muscle-Invasive Bladder CancerEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyUrology

Castration-Resistant Prostate Cancer: Darolutamide with Radiation Therapy

We are studying whether adding stereotactic radiation therapy to darolutamide helps patients with castration-resistant prostate cancer and a few metastases live longer without disease progression. We will also evaluate the treatment's safety and impact on quality of life.

Castration-Resistant Prostate Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesOncologyUrology

Hip Replacement: PENG Block vs. Lumbar Plexus Block

We are comparing two anesthesia methods for hip replacement surgery to see which one provides better pain relief and helps patients recover faster. We're also looking at hospital stay length and any side effects.

Total Hip Replacement1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOrthopedics and TraumatologyOtolaryngology

Acute Myeloid Leukemia: Venetoclax Treatment Study

We are studying whether adding venetoclax to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia live longer and achieve better treatment results. This trial compares venetoclax to a placebo to assess its impact on patient outcomes.

Acute Myeloid Leukemia6-12 monthsConfirmation phase (III)Standard MedicinesHematology

Heart Blood Flow Measurement: SYN2 PET Imaging

We are testing a new imaging method to measure blood flow in the heart for patients suspected of having coronary artery disease. The study aims to ensure this method is accurate and safe for use.

Coronary Artery Disease1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Advanced Solid Tumors: MDNA11 and Pembrolizumab Study

We are investigating the safety and effectiveness of MDNA11, given alone or with pembrolizumab, in patients with advanced solid tumors. This study aims to find the best dose and understand how the treatment works.

Solid TumorSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Breast and Gastric Cancers: Disitamab Vedotin with Tucatinib

We are studying a new combination of disitamab vedotin and tucatinib for patients with advanced breast and gastric cancers. The goal is to find the best dose and evaluate its safety and effectiveness.

HER2 Positive Breast CancerOesophageal AdenocarcinomaGastric Cancer1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Thyroid Eye Disease: VRDN-001 Treatment Study

We are testing the safety and tolerability of a new monoclonal antibody, VRDN-001, in people with thyroid eye disease. This study involves receiving intravenous infusions to see how well the treatment is tolerated.

Thyroid Eye Disease1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesEndocrinologyOphthalmology

Extracranial Malignant Germ Cell Tumors: Carboplatin vs. Cisplatin

We are comparing the effectiveness and side effects of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumors. This study aims to improve treatment options and patient quality of life.

Malignant Extracranial Germ Cell Tumours>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Pneumococcal Vaccine Study for Infants: PCV21

We are investigating a new 21-valent vaccine for healthy infants starting at 2 months old. The study aims to see if it works as well or better than the current vaccine in protecting against pneumonia.

Pneumococcal ImmunizationConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesPediatrics

Systemic Lupus Erythematosus: CABA-201 T Cell Therapy

We are studying a new T cell therapy for people with active systemic lupus erythematosus to see if it is safe and effective. This research aims to understand how it affects disease activity and overall health.

Systemic Lupus Erythematosus>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyRheumatology

Vertebral Osteomyelitis: Early Oral Antibiotics Study

We are investigating if switching to oral antibiotics after one week is as effective as continuing intravenous treatment for pyogenic vertebral osteomyelitis. This study will also assess safety, hospital stays, and quality of life for patients.

Pyogenic Vertebral Osteomyelitis3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesOrthopedics and TraumatologyRheumatology

Hepatitis B: TherVacB Vaccine Study

We are testing a new vaccine for adults with hepatitis B to see if it is safe and how well it boosts the immune response. The study will also check if it helps reduce the virus in the body.

Chronic Hepatitis B6-12 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHepatologyInfectious Diseases

Multiple Sclerosis: Ocrelizumab Access Study

We are exploring how multiple sclerosis impacts patients physically while ensuring they can continue receiving ocrelizumab treatment. This study also looks at the safety and tolerability of the medication.

Multiple Sclerosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineNeurology

HER3-DXd for Advanced Solid Tumors

We are studying a new treatment for patients with locally advanced or metastatic solid tumors to see if it is effective and safe. This trial will help us understand how well it works and its relationship with tumor characteristics.

Locally Advanced or Metastatic Solid Tumors>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Infectious Endocarditis: Shorter Antibiotic Treatment Study

We are investigating whether a shorter course of antibiotics is safe and effective for treating left-sided infectious endocarditis caused by specific bacteria. This study also looks at the potential cost benefits of this accelerated treatment.

Infectious Endocarditis≤3 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInfectious Diseases

Prostate Cancer: [225Ac]Ac-PSMA-R2 Treatment Study

We are studying a new treatment for men with advanced prostate cancer to see if it is safe and effective. This trial includes men who have been treated before and those who have not.

Advanced Prostate CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Hepatocellular Carcinoma: Durvalumab and Bevacizumab Study

We are studying whether the combination of durvalumab and bevacizumab can help prevent cancer recurrence in patients with hepatocellular carcinoma after surgery or ablation. This trial compares these treatments to a placebo to assess their effectiveness.

Early Stage Liver Cancer>2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteHepatologyOncology

Rheumatoid Arthritis: MethMax Trial

We are studying how well methotrexate works for people with active rheumatoid arthritis. The goal is to see if it helps more patients reach remission or low disease activity compared to current treatments.

Rheumatoid Arthritis3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Axial Spondyloarthritis: Risankizumab Treatment

We are studying the effects of a new treatment for patients with very early axial spondyloarthritis. The goal is to see if it can reduce disease activity and improve overall function.

Axial Spondyloarthritis6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesRheumatology